Role of clostridium difficile infection in the relapse of ulcerative colitis;Papel de la infección por clostridium difficile en la reactivación de la colitis ulcerosa

Anales de Medicina Interna

Volumn 19, Issue 12, 2002, Pages 637-639

  Vilalta Castel, E ^a,d   Alcazar Montero M S ^b   Navarro Gaspar, C ^b   Gimeno Aranguez, M ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Unidad de Digestivo   (Spain)

^c Servicio de Anatomía Patológica   (Spain)

^d NONE   (Spain)

Author keywords

Clostridium difficile; Ulcerative colitis relapse

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; SALAZOSULFAPYRIDINE; VANCOMYCIN;

AGED; ANAMNESIS; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLON BIOPSY; COLONOSCOPY; CORRELATION ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELDERLY CARE; FEMALE; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; PSEUDOMEMBRANOUS COLITIS; RELAPSE; ULCERATIVE COLITIS;

EID: 0036964319     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Moses PH, Moore BR, Ferrentino N, Bensen SP, Vecchio JA. Inflammatory bowel disease. Origin, presentation and course. Postgrad Med 1998; 103 (5): 77-84.
2. Brown VJ, Hudson MJ, Patrick J, Matthews CW, Hill MJ, Gent AE, et al. Search for Enteric Microbial Pathogens in Patients with Ulcerative Colitis. Digestion 1992; 53: 121-8.
3. Desreumaux P, Colombel JF. Intestinal microflora and cronic inflammatory bowel diseases. Gastroenterol Clin Biol 2001; 25 Spec No 2: C 89-93.
4. Farell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62.
5. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, et al. Outcome of cytomegalovirus infections in patiens with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-42.
6. Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A, et al. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis 2001; 33 (7): 551-8.
7. Hermens DJ, Miner Ph B Jr. Exacerbation of Ulcerative Colitis. Gastroenterology 1991; 101: 254-62.
8. Wang A, Takeshima F, Ikeda M, Ohnita K, Foruso H, Isomoto H, et al. Ulcerative colitis complicating pseudomembranous colitis of the right colon. J Gastroenterol 2002; 37 (4): 309-12.
9. García-Osogobio S, Takahashi T, Garnboa-Domínguez A, Medina H, Arch J, Mass W, et al. Toxic pseudomembranous colitis in a patient with ulcerative colitis, Inflamm Bowel Dis 2000; 6: 188-90.
10. Weber P, Koch M, Wolfgang RH, Scheulen M, Harro J, Hartnann F. Microbic Superinfection Relapse of Inflammatory Bowel Disease. J Clin Gastroenterol 1992; 14 (4): 302-8.
11. Meyers S, Mayer L, Bottone E, Desmond E and Janowitz HD. Occurrence of Clostridium difficile Toxin During the Course of Inflammatory Bowel Disease. Gastroenterology 1981; 80: 697-700.
12. Hartley MG, Hudson MJ, Swarbrick ET, Grace RH, Gent AE, Hellier MD. Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. Aliment Pharmacol Ther 1996, 10 (2): 157-63.
13. Sandberg-Gertzen B, Kjellander J, Sundberg-Gilla B, Jarnerot G. In vitro effects of sulfasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria. Scand J Gastroenterol 1985; 20: 607-12.
14. Tremaine WJ, Bille J, Huizenga KA, Washington JA, Ilstrup DM. Factors wich influence the ocurrence of Clostridium difficile infections in inflammatory bowel disease(abstr.). Gastroenterology 1983; 84: 1337.
15. G.Schumacher, B.Kullberg, B.Sandstedt. A prospective study of first attacks of Inflammatory Bowel Disease and Infectious Colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol 1994; 29: 318-32.
16. SV Nash, R.Bourgeault, M.Sands. Colonic disease associated with a positive assay for Clostridium difficile Toxin: A retrospective study. J Clin Gastroenterol 1997; 25 (2): 476-9.
17. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R and Mehta K. Agents in Exacerbations of Ulcerative Colitis in India. J Clin Gastroenterol 1993;16 (1): 26-30.
18. LaMont JT, Trnka Y. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; 1: 381-3.
19. Robinson M. Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl 1998; (582): 90-8.
20. Gilat T, Suissa A, Leichtman G, delpre G, Pavlotsky M, Gossman A, et al. A comparative study of metronidazole and sulfasalazine in inactive, not severe, ulcerative colitis. J Clin Gastroenterol 1987; 9: 415-7.
21. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-2.
22. Dickinson RJ, O'Connor HJ, Pinder Hamilton I, Johnston D, Axon ATR. Doubled blind controlled trial of oral vancomycin as adjuctive treatment in acute exacerbations of idiopatic colitis. Gut 1985; 26: 1380-4.